P95

Executive Summary

P95 is a Belgium-based Contract Research Organization (CRO) specializing in vaccines and infectious diseases, with a strong focus on conducting research in low- and middle-income countries (LMICs), particularly Africa. Founded in 2005, the company offers end-to-end services including clinical trial delivery, epidemiology, real-world evidence (RWE), biostatistics, and medical writing. Its niche positioning in LMICs addresses a critical gap in global health research, as many sponsors seek reliable partners for vaccine trials and disease surveillance in regions with high infectious disease burden. P95's expertise in navigating complex regulatory and operational environments in Africa provides a competitive advantage, enabling efficient patient recruitment and data collection in underserved populations. The company is well-positioned to benefit from the increasing global focus on pandemic preparedness and vaccine equity. As governments and philanthropic organizations invest in expanding clinical trial infrastructure in LMICs, P95's established presence and track record likely drive new business opportunities. While the CRO market is competitive, P95's specialization and geographic focus differentiate it. Key growth drivers include repeat contracts from existing clients, expansion of RWE services, and partnerships with global health initiatives. However, reliance on a niche segment and potential geopolitical risks in operating regions may temper growth. Overall, P95 presents a steady, specialized investment opportunity in the infectious disease CRO space.

Upcoming Catalysts (preview)

• Q3 2026Major vaccine trial contract in sub-Saharan Africa70% success
• Q4 2026Expansion of RWE capabilities through new partnership60% success
• Q2 2026Strategic collaboration with global health NGO for infectious disease surveillance50% success